![msts score msts score](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/004e11ca-5625-4f70-9f58-9326c77993a0/gr5_lrg.jpg)
An expert committee comprised of these five translators and two senior orthopedic surgeons (S.W and W.S.) reviewed all versions of the translations, and assessed conceptual equivalence of all items and discussed discrepancies. The back translation to English was performed by two bilingual translators speaking English as mother language. The translations were then combined into one single version after a round-table discussion. One of them speaks English as the mother language, and the other two are both orthopedic surgeons speaking Chinese (X.L. Briefly, the forward translation to Chinese was carried out independently by three bilingual translators. The protocol of translation of the instrument was performed as previously reported. Informed consents were obtained from all the patients.
![msts score msts score](https://www.researchgate.net/publication/348990005/figure/tbl1/AS:996221825060868@1614529200868/Musculoskeletal-Tumor-Society-MSTS-scoring-system-for-the-upper-extremity.png)
Patients’ medical records were used to collect the following demographic data, such as age, sex, tumor location, histological type of the tumor, type of surgical interventions and period of follow-up. No patient refused to complete the instrument, and there was no missing item. The MSTS score was calculated by two orthopedic surgeons independently (S.W and W.S.). A senior orthopedic surgeon (W.S.) administered the instrument to the patients. The assessment was performed at the follow-up visit of the patients. All the patients have received and completed neo-adjuvant chemotherapy for sarcoma in our center. Finally, a cohort of 98 patients including 59 male and 39 female were included in the study. without local recurrence or distant metastasis 5. with a minimum of 1 year follow-up after surgery 4. diagnosed as bone or soft-tissue sarcoma in the lower extremity 3. The following inclusion criteria were used: 1. Patients who underwent surgical treatment in our center between March 2008 and November 2015 were evaluated for the eligibility to be included in our study. The current study was approved by the local Institutional Review Board. The objectives were to investigate the reliability and validity of the Chinese MSTS scoring system, and to evaluate functional outcomes of the surgical treatment of lower extremity sarcoma with the Chinese MSTS. Therefore, in this study we applied the Chinese version of MSTS to a cohort of patients with lower extremity sarcoma. To the best of our knowledge, the validation of the Chinese version of the MSTS scoring system has not yet been reported. It has been cross-culturally adapted in the Chinese population, yielding good reliability and construct validity.
![msts score msts score](https://www.researchgate.net/publication/325462862/figure/tbl1/AS:670700176146434@1536918791175/Description-of-MSTS-score_Q320.jpg)
The TESS questionnaire of lower extremity was comprised of 29 questions rated on 5-point scale, including “impossible to do,” “extremely difficult,” “moderately difficult,” “a little bit difficult,” and “not at all difficult”. The TESS questionnaire is a self-administered questionnaire evaluating functional difficulties. The total score ranges from 0 to 30, with higher scores indicating better function. Each item was rated in a scale of 0 to 5. It is composed of six items, including pain, function, emotional acceptance, use of any external support, walking ability, and gait alteration. The original version was written in English and has only been translated and validated in Brazilian and Japanese population. The MSTS Rating Scale is a widely used functional instrument which was developed in 1983 and later modified by the MSTS in 1993. In this perspective, it is necessary to develop a disease-specific instrument for patients with extremity sarcoma to determine their perceived physical and mental health.Ĭurrently, several disease-specific instruments have been used to evaluate the functional outcome of patients with extremity tumors, such as Musculoskeletal Tumor Society (MSTS) rating scale and the Toronto Extremity Salvage Score (TESS). Therefore, it is very important to apply the most suitable treatment for each patient. It is noteworthy that patients with sarcoma may have a significant heterogeneity regarding individual factors, such as age, financial capacity and nature of the tumor. Other disadvantages of limb-salvage surgery include the increased risk of infections and breakages of the prosthesis. By contrast, limb-salvage surgery may result in long period of hospitalization and not optimally functioning outcome. Depending on the location and the progressive status of the sarcoma, amputation surgery may still be necessary, despite at the cost of compromised body image. Recently, with the development of adjuvant therapies in the form of radiation therapy and chemotherapy, more patients had the opportunity to undergo limb-salvage surgery. Previously, patients with extremity sarcoma were routinely treated by amputation surgery. Sarcoma is a rare type of cancer that most frequently in the long bones and soft-tissue of the extremity.